Visit the NEW CoM Homepage |  University of Kentucky |  UK HealthCare |  Give to Medicine |  Diversity  
UK College of Medicine logo Link to the College of Medicine web site
  • ed8
  • rs4
  • cs3
  • ad

Internal Medicine - Allergy

Internal Medicine

Allergy and Immunology

CONTACT

CURRENT STUDIES:

We are currently enrolling for 2010 in the following areas:

  • Severe Asthma
  • Ragweed Allergy

If you are interested in finding out more or to see if you qualify for one of out trials please contact:

Tonya Gardner, CCRC
(859) 257-9815


E:Mail: Tonya.Gardner

University of Kentucky
Allergy, Asthma, and Sinus Clinic
135 E. Maxwell St., Suite 250
Lexington, KY 40508


PAST STUDIES:

CLINICAL TRIALS

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study Of The Based Efficacy And Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered As Allergen-Tablets Once Daily To Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis; Protocol Number 08-0820-F6A, Stallergens, December 2008

A Randomized, Double Blind, Double Dummy, Placebo-controlled, Parallel-group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticassone Propionate Inhalation Powder 100mcg Twice Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy; Protocol Number 08-0415-F2L, GSK, August 2008

A Randomized, Double Blind, Double Dummy, Placebo-controlled, Parallel-group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticassone Propionate Inhalation Powder 250mcg Twice Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose ICS Therapy; Protocol Number 08-0414-F2L, GSK, August 2008

A Randomized, Double Blind, Double Dummy, Placebo-controlled, Parallel-group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticassone Propionate Inhalation Powder Once Daily Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate-Dose ICS Therapy; Protocol Number 08-0385-F2L, GSK, August 2008

A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS 100/50 mcg BID or Placebo BID; Protocol Number 06-0256-F3R; GSK June 2006

A 26-week, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the effect of Xolair (omalizumab) on improving the tolerability of specific immunotherapy in patients with persistent allergic asthma; Protocol Number 06-0217-F2L: Novartis, June 2006

A Phase IIIB multicenter, randomized, double-blind, placebo-controlled study of Xolair in subjects with moderate to severe persistent asthma who are inadequately controlled with Advair 500/50 BID; Protocol Number 06-0328-F3R; Genentech, June 2006

Exhaled Nitric Oxide in patients with asthma, Protocol # 05-0736-F2L, Investigator initiated, April 2006

Evaluation of Xolair’s Clinical Effectiveness and Long-term Safety, Protocol Number 04-0462-F1V; Genetech/Norvartis; October 2004

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients with Perennial Allergic Rhinitis, Protocol Number 03-0813-F3R; Merck; January 2004

A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus Salmeterol 42 mcg (2 Puffs) Twice Daily. Protocol Number 00-0487-F3R; Glaxo Wellcome, Inc.; September 2000

University HealthSystem Consortium Clinical Process Improvement Asthma Benchmarking. Adult Asthma Study, Attending Physician. April 2000

Assessment of the Relationship between Objective Measures of Disease Severity and Contingent Valuation Responses in Patients with Asthma. Protocol Number 98-50290; The American Foundation for Pharmaceutical Education; September 25, 1998

Clarithromycin in the Treatment of Mild to Moderate Acute Exacerbation of Chronic Bronchitis. Protocol Number 98-00044; Abbott Laboratories; February 28, 1998

BENCH RESEARCH

Hybridoma Production of Monoclonal Antibodies to Legionella Pneumophila Capsular Antigens. Thesis - under supervision of Dr. Randall Smith, Ph.D., Department of M&I WSU, Dayton, Ohio

Cadaveric Cartilage Harvesting & Tissue Culturing - under supervision of Dr. Jerome Herman, M.D., University of Cincinnati Medical Center, Department of Immunology, Cincinnati, Ohio

A Murine Model of Marrow Rejections: Immunoresponsiveness Induced by Priming Injections of Marrow Cells in the C3H->C57BL/6 Marrow Grafting Pair - under supervision of J. Sambrano, M.D., Department of Hematology/Oncology, Children’s Hospital Research Foundation, Cincinnati, Ohio

Cellular analysis of Bronchoalvcolar lavage fluid of asthmatic guinea pigs using FACS. University of Kentucky, Department of Medicine, Division of Allergy & Immunology, Lexington, Kentucky

Comments and Corrections |  An Equal Opportunity University |  Jobs  |  Terms, Conditions and Accessibility Statements   |  Privacy
© 2012, University of Kentucky College of Medicine, 138 Leader Ave., Lexington, Kentucky, USA 40506-9983
Student Affairs: (859) 323-5261 · Admissions: (859) 323-6161 · Clinical Questions: (859) 257-1000 · Dean's Office: (859) 323-6582
Page last updated Tuesday, January 26, 2010